Anebulo Pharmaceuticals, Inc.

NASDAQ•ANEB

CEO: Dr. Joseph F. Lawler M.D., Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-05-07

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.

連絡先情報

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, 78734, United States

512-598-0931

www.anebulo.com

時価総額

$22.43M

PER (TTM)

-2.8

17.9

配当利回り

52週高値

$3.42

52週安値

$0.30

52週レンジ

順位56Top 81.7%

2.5

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 2.5 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q2 2026 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.05+0.00%

直近4四半期の推移

フリーCF

-$1.31M+0.00%

直近4四半期の推移

2026 Q2 決算ハイライト

主なハイライト

Six Month Net Loss Reduced Six month net loss decreased to $(4.158M) USD, reflecting $506K improvement against prior period results.

R&D Spending Decreased Six month R&D expenses fell $561K USD to $1.975M, due to lower contract manufacturing activities.

Cash Position Maintained Cash and equivalents stood at $9.042M USD as of December 31, 2025, following operating cash usage.

Financing Provided Cash Inflow Financing activities provided $15.0M USD cash inflow, supporting operations before the reporting period end date.

リスク要因

Future Funding Dependency Expect continued operating losses; cash runway estimated for 12 months requiring future capital raises.

Clinical Trial Uncertainty Success hinges on favorable clinical trial results and obtaining necessary regulatory approvals for product candidates.

Going Private Liquidity Risk Plan to delist from Nasdaq; reduced public information availability may increase stock illiquidity and volatility.

Equity Dilution Risk Future equity financing or Loan Agreement stock issuance will cause substantial dilution to existing common stockholders.

見通し

Prioritizing Pediatric IV Formulation Prioritizing intravenous formulation development for pediatric indication, seeking faster regulatory pathway for emergency treatment.

IV Study Currently Ongoing Initiated ongoing single ascending dose study for IV selonabant in healthy adults during third quarter 2025.

Government Operations Disruption Risk Future government shutdowns pose risk to timely regulatory reviews, grant disbursements, and clinical trial oversight.

G&A Expenses Expected Decline General administrative expenses expected to decrease following completion of planned deregistration from SEC reporting.

同業比較

売上高 (TTM)

MGNX

$149.50M

+0.8%

ZNTL

$26.87M

-33.8%

SRZN

$3.60M

-64.0%

粗利益率 (最新四半期)

SRZN

100.0%

+0.0pp

MGNX

62.4%

+19.9pp

ANEB

0.0%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
SRZN	$216.09M	-2.5	-4404.2%	7.5%
ZNTL	$195.80M	-1.3	-51.5%	11.2%
MGNX	$189.78M	-2.6	-120.2%	41.6%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月7日

EPS:-$0.14

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし